84163-68-8

Basic information

• Product Name: 3-Piperidin-4-ylbenzo[d]isoxazole
• Synonyms: 3-PIPERIDIN-4-YL-BENZO[D]ISOXAZOLE;3-PIPERIDIN-4-YL-1H-PYRROLO[2,3-B]PYRIDINE HCL;3-(4-piperidinyl)-1,2-Benzisoxazole;3-(Piperidin-4-yl);Risperidone Related Compound HCl
• CAS NO: 84163-68-8
• Molecular Formula: C12H14N2O
• Molecular Weight: 202.25
• Product Categories: pharmacetical
• Mol File: 84163-68-8.mol

Chemical Properties

• Boiling Point: 355.519 °C at 760 mmHg
• Flash Point: 168.812 °C
• Appearance: /
• Density: 1.144 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.81±0.10(Predicted)
• CAS DataBase Reference: 3-Piperidin-4-ylbenzo[d]isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Piperidin-4-ylbenzo[d]isoxazole(84163-68-8)
• EPA Substance Registry System: 3-Piperidin-4-ylbenzo[d]isoxazole(84163-68-8)

Safety Data

• Hazardous Substances Data: 84163-68-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Piperidin-4-ylbenzo[d]isoxazole is used as a pharmaceutical agent for its potential role in the development of new drugs. Its diverse biological activities, attributed to the piperidine moiety, make it a promising candidate for further research and development.
Used in Medicinal Chemistry Research:
3-Piperidin-4-ylbenzo[d]isoxazole is utilized as a target compound in medicinal chemistry for exploring its potential as a CNS agent. Its unique structure allows for investigation into its pharmacological properties and possible applications in treating central nervous system disorders.

InChI:InChI=1/C12H14N2O/c1-2-4-11-10(3-1)12(14-15-11)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2

Upstream product

• 84163-45-1 4-(2-fluorobenzoyl)-1-methyl piperidine 
• 88284-48-4 2-(trimethylsilyl)phenyl trifluoromethanesulfonate 
• 467423-44-5 tert-butyl 4-(chloro(hydroxyimino)methyl)piperidine-1-carboxylate 
• 1198283-78-1 3-(N-boc-piperidin-4-yl)benzisoxazole 
• 84163-55-3 3-(1-methyl-4-piperidinyl)-1,2-benzisoxazole 
• 394-47-8 2-fluorobenzonitrile 
• 5570-77-4 4-chloro-1-methylpiperidine 
• 84163-21-3 phenyl 4-(1,2-benzisoxazol-3-yl)-1-piperidinecarboxylate 

Downstream Products

• 1426901-70-3 3-[1-(phenylsulfonyl)piperidin-4-yl]benzisoxazole 
• 1426901-75-8 C₁₈H₁₆Br₂N₂O₃S 
• 1426901-76-9 C₂₁H₂₂N₂O₄ 
• 84163-35-9 3-[1-(β-Phenylethyl)-4-piperidyl]-1,2-benzisoxazole hydrochloride 

Relevant articles and documents

Solution-phase synthesis of a diverse library of benzisoxazoles utilizing the [3 + 2] cycloaddition of in situ-generated nitrile oxides and arynes

A library of benzisoxazoles has been synthesized by the [3 + 2] cycloaddition of nitrile oxides with arynes and further diversified by acylation/sulfonylation and palladium-catalyzed coupling processes. The eight key intermediate benzisoxazoles have been prepared by the reaction of o-(trimethylsilyl)aryl triflates and chlorooximes in the presence of CsF in good to excellent yields under mild reaction conditions. These building blocks have been used as the key components of a diverse set of 3,5,6-trisubstituted benzisoxazoles.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

Synthesis and Neuroleptic Activity of 3-(1-Substituted-4-piperidinyl)-1,2-benzisoxazoles

The synthesis of a series of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles is described.The neuroleptic activity of the series was evaluated by utilizing the climbing mice assay and inhibition of spiroperidol binding.Structure-activity relationships were studied by variation of the substituent on the benzisoxazole ring with concomitant variation of four different 1-piperidinyl substituents.Maximum neuroleptic activity was realized when there was a 6-fluoro substituent on the benzisoxazole ring.The 1-piperidinyl substituent appeared less significant, although in most cases, the (1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl group imparted maximum potency.The most potent compound in both assays was 6-fluoro-3--4-piperidinyl>-1,2-benzisoxazole (11b).